Plateable Primary Human Hepatocytes (Cryo)

Plateable Primary Human Hepatocytes (Cryo) - Plateable Hepatocytes

The most accurate representation of in vivo cellular function and characteristics can be achieved with plateable hepatocytes. BeCytes Biotechnologies cryopreserved human plateable hepatocytes are qualified by their ability to maintain a confluent monolayer (85% confluency) for at least five days. Plateable hepatocytes cells can also be used for suspension studies.

BeCytes Biotechnologies Plateable hepatocytes cells are Cryopreserved primary human hepatocytes (HuHEC). HuHEC are human liver cells that have been isolated from healthy and pathological donor livers and preserved by cryopreservation techniques for later use in research allowing researchers to organize experiments at their convenience.

HuHEC retain important characteristics of liver cells found in the human body, and they serve as valuable tools for a wide range of research applications.

Ref. Product
HuHECP Plateable
HuHECP-30 Plateable & 3D Certified
HuHECPMI Plateable - Metabolism & Induction Certified
HuHECPMI-3D  Plateable – Metabolism, Induction Certified & 3D Qualified



The liver is the largest gland in the body, and 70–85% of liver volume is occupied by hepatocytes. Hepatocytes are specialized epithelial cells that exhibit the highly polarized architecture and organization of the cytoplasm and plasma membrane, to fulfill the multitude of tasks they are required to perform. These cells play pivotal roles in metabolism, detoxification and protein synthesis. Specifically, primary human hepatocytes are isolated directly from the liver, and they have become the “gold standard” for evaluating hepatic metabolism and the toxicity of drugs and other xenobiotics in vitro.
Primary human hepatocytes are considered the gold standard for in vitro hepatic studies, including ADME/DMPK. Although primary human hepatocytes are not proliferative cells in an in vitro culture, these cells retain most, if not all, of their original biochemical, molecular signaling pathways, along with phenotypic gene expression profiles. Conversely, immortalized cells have undergone genetic modifications that lead to uncoupled growth characteristics, and they cannot fully replicate the phenotypes found in primary hepatocytes.
Hepatocytes are determined to be either plateable or suspension based on the confluency or the percentage of a culture vessel, which is covered after plating the cells. To be considered plateable, our internal quality control department has established that the cells must create a monolayer covering around 70% of the plate’s total surface area; if the cells do not accomplish the mentioned criteria, they are considered suspension hepatocytes.Plateable hepatocytes are advantageous because they can be used for long-term culturing applications, and can be utilized in many drug metabolism and pharmacokinetics-related preclinical studies, CYP induction assays, inhibitions assays, host-pathogen interactions experiments, as well as 3D hepatic models.Suspension hepatocytes are used for short-term experiments, between 2 to 8 hours depending on how rapidly the viability decreases over time, and their applications are related to studies for compound stability, metabolite formation, inhibitions studies, uptake.
Fresh hepatocytes are the cells obtained and distributed directly after liver digestion. Our fresh samples are available in both suspension and plated forms. Ideally, fresh samples are immediately used upon arrival at the research laboratory.Cryopreserved hepatocytes are more commonly used in research, as being cryopreserved grants the flexibility to organize your experiments. Cytes can provide plated and cryopreserved hepatocytes, this last option also available in both suspension and plateable formats.But regardless of your preference for fresh or cryopreserved hepatocytes, we will work with you to provide the best possible sample to meet your research needs.
The certification of metabolism is important for many different research groups, pharmaceutical companies, and CROs. At Cytes Biotechnologies, we characterize Phase I and Phase II of metabolism to determine if hepatocytes in culture can express the initial phases of drug detoxification that occur in vivo. Phase I testing is used to determine if hepatocytes have the capacity to modify xenobiotic compounds and form active metabolites. When drugs enter the liver environment in vivo, they are first converted to metabolites by enzymes such as CYP450. Our testing ensures that this function is retained.Phase II testing is used to determine the of the compounds by the hepatocytes to form inactive metabolizes. In Phase II, enzymes including SULT and UGT convert metabolites that were the product of Phase I into water-soluble products, which can then be excreted from the liver via bile or feces. Our quality control also ensures that this function is retained.
Donor demographics including age, gender, race, BMI, smoking habit, alcohol use, and drug use are typically made available to researchers. The results of the pathological and serological tests conducted prior to liver collection are also available. Other information, including drugs administered during hospitalization, medical prescriptions used by the patient, and other relevant medical histories may also be provided.
All Cytes products come with a certificate of analysis (CoA), including data related to the donor’s medical record and histological analysis from the tissue and before isolation. It also includes the number of hepatocytes per vial and its viability post-thawing; as well as the optimal cell seeding concentration in different culture plates, number of days in cultures, and morphology pictures. Information about the enzyme expression levels, induction studies, and spheroid formation of the hepatocytes is also available.
We do not recommend splitting the primary hepatocytes, since these cells are not proliferative, and they are very sensitive.
We source liver tissue from planned surgical resections on living donors, after the patient has been informed that the resected tissue will be used for research purposes and their informed consent has been obtained to maintain ethical standards. Cytes collaborates with an extensive network of hospitals to obtain tissues, abiding by all appropriate legal channels.
Cytes Biotechnologies provides all thawing, plating, and maintenance mediums, all necessary to support every step of your research process.
An accurate cell count is vital to the success of your experiment, because both under-seeding and over-seeding influence the quality of the sample. We encourage the use of consistent techniques to measure cell viability and to ensure accuracy.Also, in our CoA we include the number of cells and the viability with the respective standard deviation for each parameter, so any client can compare their cell count to ours.
Cryopreserved hepatocytes can last several years if properly maintained. This makes them ideal for research that require the use of the same cells over several months.
Cytes have the capability to ship the cells in a dry liquid nitrogen vapor transporter or on dry ice, depending on the customer’s destination to ensure that the cells arrive in perfect condition. We recommend immediately placing the cryogenic hepatocytes vials into the gas phase of the liquid nitrogen tank when the cells arrive to the facilities.
Cryopreserved 3D spheroid qualified human hepatocytes are primary hepatocytes, which have the ability to self-assemble into a 3D spheroid by using our protocol, ultra-low attachment plates and our 3D plating and maintenance medium.
1. Do not leave hepatocytes floating in the cryopreservation medium for too long if you don’t want to lose viability:· After removing the cryopreserved hepatocytes from the liquid nitrogen, immediately place them at 37ºC in a water bath until the cell suspension is partially thawed.· Quick transfer hepatocytes into a preheated thawing medium.2. Seed the correct cell density to obtain a confluent monolayer of hepatocytes: Evenly distribute the cells throughout by manually shaking the plate in a T-shape and checking it under a microscope.· Incubate the cells at 37ºC and move the plate in a T-shape every 15 minutes for the first hour.· For 96-well plates, initially dose 60uL of a pre-heated plating medium and then add the cells to the well.
Cytes do not recommend exposing primary hepatocytes to repeated freezing and thawing cycles, due to the additional stress and damage imposed on the cells and their subcellular components.